$11.13
-0.87 (-7.25%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INKT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailureNCT07615010Number of Deaths (All-cause Mortality)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: agenT-797, Placebo, Standard of Care (SOC) | Pneumonia | 90 | Jun 2027 | ≤ 314 d | 2026-06-26 |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsNCT05108623Number Of Participants With Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: agenT-797, Approved ICIs | Tumor, Solid | 34 | 2024-01-02actual | — | 2024-04-24 |
| A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSNCT04582201Number of Participants with Treatment-emergent Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: agenT-797 | Respiratory Distress Syndrome, Adult | 20 | 2023-04-23actual | — | 2025-12-30 |
| agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaNCT04754100Number Of Participants With Treatment-related Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: agenT-797 | Relapsed/Refractory Multiple Myeloma | 13 | 2023-01-13actual | — | 2023-06-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19